Commitments and Contingencies - Portfolio of CFTR Activators and Inhibitors - Narrative (Details) - CFTR Activators and Inhibitors - USD ($) $ in Millions |
9 Months Ended | 115 Months Ended |
|---|---|---|
Sep. 30, 2026 |
Sep. 30, 2026 |
|
| Commitments and Contingencies [Line Items] | ||
| Future percentage of royalty payments based net sales | single-digit | |
| Development and milestone obligations paid to third party | $ 1.8 | |
| Developmental Milestone | ||
| Commitments and Contingencies [Line Items] | ||
| Possible future milestone payments | $ 11.9 | |
| Future Regulatory Approval and Sales Milestones | ||
| Commitments and Contingencies [Line Items] | ||
| Possible future milestone payments | 33.0 | |
| Development and Milestone Payment, Conclusion of Clinical Studies | ||
| Commitments and Contingencies [Line Items] | ||
| Possible future milestone payments | 1.1 | |
| Development and Milestone Payment, Conclusion of Clinical Studies | Maximum | ||
| Commitments and Contingencies [Line Items] | ||
| Possible future milestone payments | $ 3.2 |